NCOA3 and inflammatory bowel disease: This mechanism highlights its potential in treating IBD and autoimmune disorders (54).CircRNACCND1 sponges miR-142-5p, thereby alleviating its inhibitory effect on Nuclear Receptor Coactivator 3(NCOA3) and restoring NCOA3-mediated anti-inflammatory activity (35).